Weiss Ratings Reaffirms “Sell (E+)” Rating for 60 Degrees Pharmaceuticals (NASDAQ:SXTP)

60 Degrees Pharmaceuticals (NASDAQ:SXTP)‘s stock had its “sell (e+)” rating restated by investment analysts at Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

Separately, HC Wainwright restated a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a report on Friday, January 10th.

60 Degrees Pharmaceuticals Price Performance

Shares of SXTP stock opened at $0.53 on Wednesday. The stock has a market capitalization of $3.11 million, a PE ratio of -0.05 and a beta of 4.22. 60 Degrees Pharmaceuticals has a 1-year low of $0.45 and a 1-year high of $7.20. The business has a 50-day moving average of $0.99 and a 200 day moving average of $1.09.

Insiders Place Their Bets

In other 60 Degrees Pharmaceuticals news, CEO Geoffrey S. Dow acquired 35,823 shares of the company’s stock in a transaction on Monday, December 9th. The stock was acquired at an average price of $1.27 per share, for a total transaction of $45,495.21. Following the acquisition, the chief executive officer now owns 94,580 shares in the company, valued at $120,116.60. This represents a 60.97 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. In the last 90 days, insiders acquired 60,372 shares of company stock worth $76,975. 10.27% of the stock is currently owned by company insiders.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.